156 related articles for article (PubMed ID: 11090641)
1. Adenosine A(2A) receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats.
Koga K; Kurokawa M; Ochi M; Nakamura J; Kuwana Y
Eur J Pharmacol; 2000 Nov; 408(3):249-55. PubMed ID: 11090641
[TBL] [Abstract][Full Text] [Related]
2. Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP.
Shiozaki S; Ichikawa S; Nakamura J; Kitamura S; Yamada K; Kuwana Y
Psychopharmacology (Berl); 1999 Nov; 147(1):90-5. PubMed ID: 10591873
[TBL] [Abstract][Full Text] [Related]
3. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease.
Bibbiani F; Oh JD; Petzer JP; Castagnoli N; Chen JF; Schwarzschild MA; Chase TN
Exp Neurol; 2003 Nov; 184(1):285-94. PubMed ID: 14637099
[TBL] [Abstract][Full Text] [Related]
4. Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats.
Fenu S; Pinna A; Ongini E; Morelli M
Eur J Pharmacol; 1997 Feb; 321(2):143-7. PubMed ID: 9063681
[TBL] [Abstract][Full Text] [Related]
5. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638
[TBL] [Abstract][Full Text] [Related]
6. Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
Pérez V; Sosti V; Rubio A; Barbanoj M; Rodríguez-Alvarez J; Kulisevsky J
Eur J Pharmacol; 2007 Dec; 576(1-3):83-90. PubMed ID: 17888901
[TBL] [Abstract][Full Text] [Related]
7. KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity.
Kanda T; Shiozaki S; Shimada J; Suzuki F; Nakamura J
Eur J Pharmacol; 1994 May; 256(3):263-8. PubMed ID: 8045270
[TBL] [Abstract][Full Text] [Related]
8. The alpha 2-adrenoceptor antagonist atipamezole potentiates anti-Parkinsonian effects and can reduce the adverse cardiovascular effects of dopaminergic drugs in rats.
Haapalinna A; Leino T; Heinonen E
Naunyn Schmiedebergs Arch Pharmacol; 2003 Nov; 368(5):342-51. PubMed ID: 14566451
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists.
Petzer JP; Steyn S; Castagnoli KP; Chen JF; Schwarzschild MA; Van der Schyf CJ; Castagnoli N
Bioorg Med Chem; 2003 Apr; 11(7):1299-310. PubMed ID: 12628657
[TBL] [Abstract][Full Text] [Related]
10. Distribution of adenosine A(2A) receptor antagonist KW-6002 and its effect on gene expression in the rat brain.
Aoyama S; Koga K; Mori A; Miyaji H; Sekine S; Kase H; Uchimura T; Kobayashi H; Kuwana Y
Brain Res; 2002 Oct; 953(1-2):119-25. PubMed ID: 12384245
[TBL] [Abstract][Full Text] [Related]
11. Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice.
Xiao D; Bastia E; Xu YH; Benn CL; Cha JH; Peterson TS; Chen JF; Schwarzschild MA
J Neurosci; 2006 Dec; 26(52):13548-55. PubMed ID: 17192438
[TBL] [Abstract][Full Text] [Related]
12. Effect of acute L-Dopa pretreatment on apomorphine-induced rotational behavior in a rat model of Parkinson's disease.
Mandel RJ
Exp Neurol; 2000 Jan; 161(1):212-9. PubMed ID: 10683287
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson's disease and cognition.
Mihara T; Mihara K; Yarimizu J; Mitani Y; Matsuda R; Yamamoto H; Aoki S; Akahane A; Iwashita A; Matsuoka N
J Pharmacol Exp Ther; 2007 Nov; 323(2):708-19. PubMed ID: 17684118
[TBL] [Abstract][Full Text] [Related]
14. Synergistic effects of adenosine A2A antagonist and L-DOPA on rotational behaviors in 6-hydroxydopamine-induced hemi-Parkinsonian mouse model.
Matsuya T; Takuma K; Sato K; Asai M; Murakami Y; Miyoshi S; Noda A; Nagai T; Mizoguchi H; Nishimura S; Yamada K
J Pharmacol Sci; 2007 Mar; 103(3):329-32. PubMed ID: 17341841
[TBL] [Abstract][Full Text] [Related]
15. Adenosine A2A receptors modify motor function in MPTP-treated common marmosets.
Kanda T; Tashiro T; Kuwana Y; Jenner P
Neuroreport; 1998 Aug; 9(12):2857-60. PubMed ID: 9760134
[TBL] [Abstract][Full Text] [Related]
16. Dual target strategy: combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates L-DOPA-induced rotational behavior in a rodent model of Parkinson's disease.
Fuzzati-Armentero MT; Cerri S; Levandis G; Ambrosi G; Montepeloso E; Antoninetti G; Blandini F; Baqi Y; Müller CE; Volpini R; Costa G; Simola N; Pinna A
J Neurochem; 2015 Aug; 134(4):740-7. PubMed ID: 25962878
[TBL] [Abstract][Full Text] [Related]
17. Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats.
Pinna A; Fenu S; Morelli M
Synapse; 2001 Mar; 39(3):233-8. PubMed ID: 11284438
[TBL] [Abstract][Full Text] [Related]
18. Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys.
Grondin R; Bédard PJ; Hadj Tahar A; Grégoire L; Mori A; Kase H
Neurology; 1999 May; 52(8):1673-7. PubMed ID: 10331698
[TBL] [Abstract][Full Text] [Related]
19. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats.
Tronci E; Simola N; Borsini F; Schintu N; Frau L; Carminati P; Morelli M
Eur J Pharmacol; 2007 Jul; 566(1-3):94-102. PubMed ID: 17445798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
